Synapse - Works

Results (116624)

An ongoing pilot study of targeted radioimmunotherapy (131-I apamistamab) conditioning prior to CD19-targeted CAR T-cell therapy for relapsed or refractory B-cell acute lymphoblastic leukemia or diffuse large B-cell lymphoma

Meeting Abstract

Geyer, M. B.; Cadzin, B.; Hosszu, K.; Senechal, B.; Spross, J. A.; Mark, A.; Desai, A.; Cathcart, E. R.; Palomba, M. L.; Pandit-Taskar, N.
Blood (2022)

Fulltext@MSK | Save

Safety, tolerability, PK/PD and preliminary efficacy of NKTR-255, a novel IL-15 receptor agonist, in patients with relapsed/refractory hematologic malignancies

Meeting Abstract

Patel, K.; Shah, N.; Tan, A.; Cowan, A. J.; Turtle, C. J.; Hofmeister, C. C.; Choi, T.; Saeed, H.; Chavez, J. C.; Pianko, M. J.; more...
Blood (2022)

Fulltext@MSK | Save

Standard cytogenetic risk stratification is not predictive of CD19 CAR outcomes and impact of disease burden varies between cytogenetic risk groups

Meeting Abstract

Molina, J. C.; Chinnabhandar, V.; Fabrizio, V. A.; Kunicki, M.; Pacenta, H.; Rossoff, J.; Stefanski, H. E.; Talano, J.; Moskop, A.; Verneris, M. R.; more...
Blood (2022)

Fulltext@MSK | Save

Obesity associates with inferior outcomes and toxicity in pediatric and young adult patient with relapsed/ refractory B-cell acute lymphoblastic leukemia treated with commercially manufactured tisagenlecleucel

Meeting Abstract

Ross, A. J.; Baggott, C.; Prabhu, S.; Pacenta, H.; Philips, C.; Rossoff, J.; Stefanski, H. E.; Talano, J.; Moskop, A.; Baumeister, S. H. C.; more...
Blood (2022)

Fulltext@MSK | Save

Immune escape after allogeneic hematopoietic cell transplantation in pediatric patients with acute myeloid leukemia

Meeting Abstract

Shahid, S.; Ceglia, N.; Le Luduec, J. B.; McPherson, A.; Spitzer, B.; Bojilova, V.; Panjwani, M. K.; Roshal, M.; Shah, S.; Abdel-Wahab, O.; more...
Blood (2022)

Fulltext@MSK | Save

The development of allogeneic tips-derived TCR(-)CAR(+) CD8αβ T cells

Meeting Abstract

van der Stegen, S. J. C.; Petrovic, R. M.; Lindenbergh, P. L.; Diop, M. P.; Alexeeva, V.; Xie, H.; Clarke, R.; Valamehr, B.; Rivière, I.; Sadelain, M.
Blood (2022)

Fulltext@MSK | Save

A comparison of overall survival with brexucabtagene autoleucel (brexu-cel) CAR T-cell therapy (ZUMA-2) and standard of care (SCHOLAR-2) in patients with relapsed/refractory mantle cell lymphoma (R/R MCL) previously treated with a covalent bruton tyrosine kinase inhibitor (BTKi)

Meeting Abstract

Hess, G.; Dreyling, M.; Oberic, L.; Gine, E.; Zinzani, P. L.; Linton, K. M.; Vilmar, A.; Jerkeman, M.; Chen, J. M. H.; Ohler, A.; more...
Blood (2022)

Fulltext@MSK | Save

A phase I study of FT538, an off-the-shelf, multiplexed-engineered, iPSC-derived NK cell therapy in combination with daratumumab in relapsed/refractory multiple myeloma

Meeting Abstract

Juckett, M.; Mailankody, S.; Eghtedar, A.; Bickers, C.; Zong, X.; Wong, L.; Ly, T.; Byon, J.; Cooley, S.; Valamehr, B.; more...
Blood (2022)

Fulltext@MSK | Save

MajesTEC-7: A phase 3, randomized study of teclistamab + daratumumab + lenalidomide (Tec-DR) versus daratumumab + lenalidomide + dexamethasone (DRd) in patients with newly diagnosed multiple myeloma who are either ineligible or not intended for autologous stem cell transplant

Meeting Abstract

Krishnan, A. Y.; Manier, S.; Terpos, E.; Usmani, S.; Khan, J.; Pearson, R.; Girgis, S.; Guo, Y.; McAleer, D.; Olyslager, Y.; more...
Blood (2022)

Fulltext@MSK | Save

Daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM): Updated analysis of the phase 3 MAIA study

Meeting Abstract

Kumar, S. K.; Moreau, P.; Bahlis, N. J.; Facon, T.; Plesner, T.; Orlowski, R. Z.; Basu, S.; Nahi, H.; Hulin, C.; Quach, H.; more...
Blood (2022)

Fulltext@MSK | Save